ASU researcher awarded $1.25M to develop programmable, targeted drugs
![Graphic illustration of a target over a protein.](/sites/default/files/styles/block_image_16_9_lge/public/2024-07/iStock-1798892540.jpg?itok=bTt4DG2O)
Photo courtesy iStock/Getty Images
In a significant stride for medical research, Hao Yan, a professor in Arizona State University’s School of Molecular Sciences and the Biodesign Center for Molecular Design and Biomimetics, has been awarded a $1.25 million grant from the National Institutes of Health (NIH). The grant, provided by the National Institute of General Medical Sciences (NIGMS), will fund Yan’s innovative research into programmable, targeted therapeutics.
Targeted protein degradation (TPD) is a new approach in drug development that focuses on breaking down disease-causing proteins inside cells. Traditional drugs usually work by blocking the activity of specific proteins. However, about 85% of proteins in cells are considered "undruggable" with these traditional methods because they can't be effectively targeted by small-molecule drugs.
TPD therapies take a different approach by using the cell's natural system for breaking down proteins to completely remove these problematic proteins. This method is especially useful for targeting proteins that are hard to inhibit directly. One type of TPD therapy, called proteolysis-targeting chimeras (PROTACs), uses the cell's ubiquitin-proteasome system — which is like the cell's trash disposal unit — to selectively degrade these tough-to-target proteins. While PROTACs have shown promise and some are already being tested in clinical trials, there are still significant challenges and opportunities for further development in this field.
Yan’s project addresses unmet needs in targeted protein degradation therapeutics and develops a series of programmable and conditional PROTACs enabled by nucleic acid nanotechnology.
“We are excited to receive this award from NIGMS to support our programmable and conditional PROTAC platforms,” Yan said, “and we believe we could utilize the high programmability of DNA nanotechnology to address some of the unmet yet important challenges in this field.”
To improve current methods, developing an effective drug delivery system that can activate the breakdown of target proteins only under certain conditions is crucial. Nucleic acid-based techniques, which have already shown success in medicine with drugs like antisense oligonucleotides (ASOs), offer great potential for advancing targeted protein degradation.
By using the natural programmability of DNA, researchers like Yan aim to create a precise way to deliver these protein-degrading therapies into cells and activate them only when needed.
More University news
![Person wearing a black backward cap and grey sweater, seated at a wooden table with a laptop and an open book.](/sites/default/files/styles/block_image_16_9_med/public/2024-08/EmilyK_Studying_SideView_7_2019.jpg?itok=Y6-O71_p)
Uber, ASU partnership celebrates 5 years
By Lauren IkennAs Arizona State University continues to push the boundaries of innovation and accessibility in higher education, the university’s partnership with Uber stands out as an example of how…
2 ASU honors students awarded Killam Fellowships for study in Canada
The Lorraine W. Frank Office of National Scholarships Advisement has announced that two students from Barrett, the Honors College at Arizona State University have been awarded Killam Fellowships for…
![ASU sign surrounded by palo verde blooms.](/sites/default/files/styles/block_image_16_9_med/public/2024-08/20220406PaloVerdeBlooms_034.jpg?itok=X242_eCX)
ASU Professor Joan McGregor named new director of Lincoln Center for Applied Ethics
Arizona State University’s Lincoln Center for Applied Ethics welcomed Joan McGregor, a professor for the School of Historical, Philosophical and Religious Studies, as its new director on Aug. 15…